Medical Disclaimer: This article is for informational purposes only and does not constitute legal or medical advice. Regulatory requirements for compounding pharmacies are complex and subject to change. Consult a licensed healthcare attorney or your state board of pharmacy for guidance on specific compounding questions.
For patients, physicians, and compounding pharmacies navigating the peptide landscape in 2026, regulatory clarity has been elusive. A series of guidance documents, policy reviews, and enforcement communications between mid-2025 and early 2026 have reshaped how the FDA approaches compounded peptides. Here is what changed and what it means.
Background: How FDA Regulates Compounded Peptides
Compounded medications — drugs prepared by a licensed pharmacy for a specific patient or facility — operate under a different regulatory framework than FDA-approved commercial drugs. The key statutes are:
- Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act): Governs traditional compounding pharmacies preparing medications for individual patients with valid prescriptions.
- Section 503B: Governs outsourcing facilities that can prepare larger batches for healthcare facilities without patient-specific prescriptions, subject to more rigorous FDA oversight.
Peptides used in compounding must appear on the FDA’s approved bulk drug substances list — or be under active review — to be lawfully compounded under 503A. The FDA maintains three categories for substances under consideration:
- Category 1: Recommended for inclusion — legal to compound
- Category 2: Under review — may be compounded while FDA evaluates
- Category 3: Not recommended for inclusion — not legal to compound
Key Regulatory Changes in 2025–2026
1. Enforcement Discretion Memo (January 2026)
The most significant practical development was a January 2026 interim guidance memo issued by the FDA’s Office of Pharmaceutical Quality. The memo formalized a policy of enforcement discretion for Category 2 peptides being compounded by licensed 503A pharmacies with valid individual prescriptions.
In practical terms: the FDA signaled it would not initiate regulatory action against pharmacies compounding Category 2 peptides (including BPC-157, TB-500, AOD-9604, and GHK-Cu) while the evaluation process continues, provided the pharmacy operates in compliance with all other 503A requirements.
This memo did not change the legal status of these peptides — it simply reflected the FDA’s prioritization of enforcement resources toward more serious violations, including unapproved bulk sales and Category 3 compounding.
2. Expanded Category 1 List
Following the HHS policy review in mid-2025, the FDA added several peptides to the Category 1 (approved for compounding) list, including:
- Sermorelin (already Category 1, reaffirmed)
- Ipamorelin (confirmed Category 1)
- CJC-1295 without DAC (confirmed Category 1)
- PT-141 (Bremelanotide) (reaffirmed)
- Tesamorelin (reaffirmed for 503A and 503B)
This expansion provided clarity for compounding pharmacies and prescribing physicians that had been operating under uncertainty about several growth hormone-releasing peptides.
3. Crackdown on Unapproved Internet Sales
Concurrent with the enforcement discretion memo for licensed pharmacies, the FDA increased enforcement activity against online sellers offering peptide vials, nasal sprays, and sublingual preparations without prescriptions. Multiple warning letters and injunctions were issued in 2025–2026 against entities marketing compounded peptides directly to consumers without physician involvement.
This enforcement posture reflects the FDA’s distinction between legitimate 503A compounding (physician-prescribed, pharmacy-dispensed, individual patient) and unapproved drug sales (consumer-direct, no prescription, no physician oversight).
4. Semaglutide and Tirzepatide Shortage Designation Update
In early 2026, the FDA formally removed semaglutide and tirzepatide from the drug shortage list, which had previously allowed 503A and 503B pharmacies to compound these GLP-1 medications. With shortage designation removed, the legal basis for most compounded GLP-1 formulations became significantly narrower.
503A pharmacies may still compound semaglutide for patients with documented allergies to inactive ingredients in brand-name formulations, but bulk compounding by 503B outsourcing facilities for general use is no longer authorized under the shortage exception.
What Consumers Should Know
If you receive a compounded peptide from a licensed pharmacy with a valid prescription: You are operating within the current regulatory framework for Category 1 and Category 2 peptides.
If you are purchasing peptides online without a prescription: You are likely buying an unapproved drug product. These products have not been evaluated for safety, potency, or sterility by any regulatory body.
If you use compounded semaglutide or tirzepatide: You should consult your physician about the changed legal landscape now that shortage designation has been removed. Some 503A pharmacies continue to compound these substances under narrow exemptions; verify your pharmacy’s legal basis with them directly.
Monitor Category 2 status: Several peptides consumers use — including BPC-157 and TB-500 — could move to Category 3 in 2026. Stay informed through trusted sources like the Alliance for Pharmacy Compounding or consult your prescribing physician.
Where to Find Official Information
- FDA Bulk Drug Substances List (503A): FDA.gov/drugs/human-drug-compounding
- Compounding pharmacy licensing status: Your state board of pharmacy
- Adverse event reporting: FDA MedWatch (1-800-FDA-1088)
Sources: FDA Draft Guidance on 503A Bulk Drug Substances (2025); Federal Register — Drug Compounding (January 2026); HHS Policy Review (2025). This article reflects publicly available regulatory information as of April 2026.
Stay Informed on Peptide Research
Get the latest peptide research, regulatory updates, and clinical findings delivered to your inbox weekly. No spam — unsubscribe anytime.
No spam. Unsubscribe at any time. See our Privacy Policy.